Paragangliomas arise through an autonomous vasculo-angio-neurogenic program inhibited by imatinib

Fabio Verginelli, Silvia Perconti, Simone Vespa, Francesca Schiavi, Sampath Chandra Prasad, Paola Lanuti, Alessandro Cama, Lorenzo Tramontana, Diana Liberata Esposito, Simone Guarnieri, Artenca Sheu, Mattia Russel Pantalone, Rosalba Florio, Annalisa Morgano, Cosmo Rossi, Giuseppina Bologna, Marco Marchisio, Andrea D'Argenio, Elisa Taschin, Rosa VisoneGiuseppe Opocher, Angelo Veronese, Carlo T Paties, Vinagolu K Rajasekhar, Cecilia Söderberg-Nauclér, Mario Sanna, Lavinia Vittoria Lotti, Renato Mariani-Costantini

Research output: Contribution to journalArticle

Abstract

Tumours can be viewed as aberrant tissues or organs sustained by tumorigenic stem-like cells that engage into dysregulated histo/organogenetic processes. Paragangliomas, prototypical organoid tumours constituted by dysmorphic variants of the vascular and neural tissues found in normal paraganglia, provide a model to test this hypothesis. To understand the origin of paragangliomas, we built a biobank comprising 77 cases, 18 primary cultures, 4 derived cell lines, 80 patient-derived xenografts and 11 cell-derived xenografts. We comparatively investigated these unique complementary materials using morphofunctional, ultrastructural and flow cytometric assays accompanied by microRNA studies. We found that paragangliomas contain stem-like cells with hybrid mesenchymal/vasculoneural phenotype, stabilized and expanded in the derived cultures. The viability and growth of such cultures depended on the downregulation of the miR-200 and miR-34 families, which allowed high PDGFRA and ZEB1 protein expression levels. Both tumour tissue- and cell culture-derived xenografts recapitulated the vasculoneural paraganglioma structure and arose from mesenchymal-like cells through a fixed developmental sequence. First, vasculoangiogenesis organized the microenvironment, building a perivascular niche which in turn supported neurogenesis. Neuroepithelial differentiation was associated with severe mitochondrial dysfunction, not present in cultured paraganglioma cells, but acquired in vivo during xenograft formation. Vasculogenesis was the Achilles' heel of xenograft development. In fact, imatinib, that targets endothelial-mural signalling, blocked paraganglioma xenograft formation (11 xenografts from 12 cell transplants in the control group versus 2 out of 10 in the treated group, P = 0.0015). Overall our key results were unaffected by the SDHx gene carrier status of the patient, characterized for 70 out of 77 cases. In conclusion, we explain the biphasic vasculoneural structure of paragangliomas and identify an early and pharmacologically actionable phase of paraganglioma organization.

Original languageEnglish
Pages (from-to)779-798
Number of pages20
JournalActa Neuropathologica
Volume135
Issue number5
DOIs
Publication statusPublished - May 2018

Fingerprint

Paraganglioma
Heterografts
Stem Cells
Organoids
Choristoma
Neoplasms
Imatinib Mesylate
Neurogenesis
MicroRNAs
Blood Vessels
Cultured Cells
Down-Regulation
Cell Culture Techniques
Organizations
Transplants
Phenotype
Cell Line
Control Groups
Growth

Cite this

Verginelli, F., Perconti, S., Vespa, S., Schiavi, F., Prasad, S. C., Lanuti, P., ... Mariani-Costantini, R. (2018). Paragangliomas arise through an autonomous vasculo-angio-neurogenic program inhibited by imatinib. Acta Neuropathologica, 135(5), 779-798. https://doi.org/10.1007/s00401-017-1799-2

Paragangliomas arise through an autonomous vasculo-angio-neurogenic program inhibited by imatinib. / Verginelli, Fabio; Perconti, Silvia; Vespa, Simone; Schiavi, Francesca; Prasad, Sampath Chandra; Lanuti, Paola; Cama, Alessandro; Tramontana, Lorenzo; Esposito, Diana Liberata; Guarnieri, Simone; Sheu, Artenca; Pantalone, Mattia Russel; Florio, Rosalba; Morgano, Annalisa; Rossi, Cosmo; Bologna, Giuseppina; Marchisio, Marco; D'Argenio, Andrea; Taschin, Elisa; Visone, Rosa; Opocher, Giuseppe; Veronese, Angelo; Paties, Carlo T; Rajasekhar, Vinagolu K; Söderberg-Nauclér, Cecilia; Sanna, Mario; Lotti, Lavinia Vittoria; Mariani-Costantini, Renato.

In: Acta Neuropathologica, Vol. 135, No. 5, 05.2018, p. 779-798.

Research output: Contribution to journalArticle

Verginelli, F, Perconti, S, Vespa, S, Schiavi, F, Prasad, SC, Lanuti, P, Cama, A, Tramontana, L, Esposito, DL, Guarnieri, S, Sheu, A, Pantalone, MR, Florio, R, Morgano, A, Rossi, C, Bologna, G, Marchisio, M, D'Argenio, A, Taschin, E, Visone, R, Opocher, G, Veronese, A, Paties, CT, Rajasekhar, VK, Söderberg-Nauclér, C, Sanna, M, Lotti, LV & Mariani-Costantini, R 2018, 'Paragangliomas arise through an autonomous vasculo-angio-neurogenic program inhibited by imatinib', Acta Neuropathologica, vol. 135, no. 5, pp. 779-798. https://doi.org/10.1007/s00401-017-1799-2
Verginelli, Fabio ; Perconti, Silvia ; Vespa, Simone ; Schiavi, Francesca ; Prasad, Sampath Chandra ; Lanuti, Paola ; Cama, Alessandro ; Tramontana, Lorenzo ; Esposito, Diana Liberata ; Guarnieri, Simone ; Sheu, Artenca ; Pantalone, Mattia Russel ; Florio, Rosalba ; Morgano, Annalisa ; Rossi, Cosmo ; Bologna, Giuseppina ; Marchisio, Marco ; D'Argenio, Andrea ; Taschin, Elisa ; Visone, Rosa ; Opocher, Giuseppe ; Veronese, Angelo ; Paties, Carlo T ; Rajasekhar, Vinagolu K ; Söderberg-Nauclér, Cecilia ; Sanna, Mario ; Lotti, Lavinia Vittoria ; Mariani-Costantini, Renato. / Paragangliomas arise through an autonomous vasculo-angio-neurogenic program inhibited by imatinib. In: Acta Neuropathologica. 2018 ; Vol. 135, No. 5. pp. 779-798.
@article{0be23dc7859547cba6e8c2efec38ab5b,
title = "Paragangliomas arise through an autonomous vasculo-angio-neurogenic program inhibited by imatinib",
abstract = "Tumours can be viewed as aberrant tissues or organs sustained by tumorigenic stem-like cells that engage into dysregulated histo/organogenetic processes. Paragangliomas, prototypical organoid tumours constituted by dysmorphic variants of the vascular and neural tissues found in normal paraganglia, provide a model to test this hypothesis. To understand the origin of paragangliomas, we built a biobank comprising 77 cases, 18 primary cultures, 4 derived cell lines, 80 patient-derived xenografts and 11 cell-derived xenografts. We comparatively investigated these unique complementary materials using morphofunctional, ultrastructural and flow cytometric assays accompanied by microRNA studies. We found that paragangliomas contain stem-like cells with hybrid mesenchymal/vasculoneural phenotype, stabilized and expanded in the derived cultures. The viability and growth of such cultures depended on the downregulation of the miR-200 and miR-34 families, which allowed high PDGFRA and ZEB1 protein expression levels. Both tumour tissue- and cell culture-derived xenografts recapitulated the vasculoneural paraganglioma structure and arose from mesenchymal-like cells through a fixed developmental sequence. First, vasculoangiogenesis organized the microenvironment, building a perivascular niche which in turn supported neurogenesis. Neuroepithelial differentiation was associated with severe mitochondrial dysfunction, not present in cultured paraganglioma cells, but acquired in vivo during xenograft formation. Vasculogenesis was the Achilles' heel of xenograft development. In fact, imatinib, that targets endothelial-mural signalling, blocked paraganglioma xenograft formation (11 xenografts from 12 cell transplants in the control group versus 2 out of 10 in the treated group, P = 0.0015). Overall our key results were unaffected by the SDHx gene carrier status of the patient, characterized for 70 out of 77 cases. In conclusion, we explain the biphasic vasculoneural structure of paragangliomas and identify an early and pharmacologically actionable phase of paraganglioma organization.",
author = "Fabio Verginelli and Silvia Perconti and Simone Vespa and Francesca Schiavi and Prasad, {Sampath Chandra} and Paola Lanuti and Alessandro Cama and Lorenzo Tramontana and Esposito, {Diana Liberata} and Simone Guarnieri and Artenca Sheu and Pantalone, {Mattia Russel} and Rosalba Florio and Annalisa Morgano and Cosmo Rossi and Giuseppina Bologna and Marco Marchisio and Andrea D'Argenio and Elisa Taschin and Rosa Visone and Giuseppe Opocher and Angelo Veronese and Paties, {Carlo T} and Rajasekhar, {Vinagolu K} and Cecilia S{\"o}derberg-Naucl{\'e}r and Mario Sanna and Lotti, {Lavinia Vittoria} and Renato Mariani-Costantini",
year = "2018",
month = "5",
doi = "10.1007/s00401-017-1799-2",
language = "English",
volume = "135",
pages = "779--798",
journal = "Acta Neuropathologica",
issn = "0001-6322",
publisher = "Springer Verlag",
number = "5",

}

TY - JOUR

T1 - Paragangliomas arise through an autonomous vasculo-angio-neurogenic program inhibited by imatinib

AU - Verginelli, Fabio

AU - Perconti, Silvia

AU - Vespa, Simone

AU - Schiavi, Francesca

AU - Prasad, Sampath Chandra

AU - Lanuti, Paola

AU - Cama, Alessandro

AU - Tramontana, Lorenzo

AU - Esposito, Diana Liberata

AU - Guarnieri, Simone

AU - Sheu, Artenca

AU - Pantalone, Mattia Russel

AU - Florio, Rosalba

AU - Morgano, Annalisa

AU - Rossi, Cosmo

AU - Bologna, Giuseppina

AU - Marchisio, Marco

AU - D'Argenio, Andrea

AU - Taschin, Elisa

AU - Visone, Rosa

AU - Opocher, Giuseppe

AU - Veronese, Angelo

AU - Paties, Carlo T

AU - Rajasekhar, Vinagolu K

AU - Söderberg-Nauclér, Cecilia

AU - Sanna, Mario

AU - Lotti, Lavinia Vittoria

AU - Mariani-Costantini, Renato

PY - 2018/5

Y1 - 2018/5

N2 - Tumours can be viewed as aberrant tissues or organs sustained by tumorigenic stem-like cells that engage into dysregulated histo/organogenetic processes. Paragangliomas, prototypical organoid tumours constituted by dysmorphic variants of the vascular and neural tissues found in normal paraganglia, provide a model to test this hypothesis. To understand the origin of paragangliomas, we built a biobank comprising 77 cases, 18 primary cultures, 4 derived cell lines, 80 patient-derived xenografts and 11 cell-derived xenografts. We comparatively investigated these unique complementary materials using morphofunctional, ultrastructural and flow cytometric assays accompanied by microRNA studies. We found that paragangliomas contain stem-like cells with hybrid mesenchymal/vasculoneural phenotype, stabilized and expanded in the derived cultures. The viability and growth of such cultures depended on the downregulation of the miR-200 and miR-34 families, which allowed high PDGFRA and ZEB1 protein expression levels. Both tumour tissue- and cell culture-derived xenografts recapitulated the vasculoneural paraganglioma structure and arose from mesenchymal-like cells through a fixed developmental sequence. First, vasculoangiogenesis organized the microenvironment, building a perivascular niche which in turn supported neurogenesis. Neuroepithelial differentiation was associated with severe mitochondrial dysfunction, not present in cultured paraganglioma cells, but acquired in vivo during xenograft formation. Vasculogenesis was the Achilles' heel of xenograft development. In fact, imatinib, that targets endothelial-mural signalling, blocked paraganglioma xenograft formation (11 xenografts from 12 cell transplants in the control group versus 2 out of 10 in the treated group, P = 0.0015). Overall our key results were unaffected by the SDHx gene carrier status of the patient, characterized for 70 out of 77 cases. In conclusion, we explain the biphasic vasculoneural structure of paragangliomas and identify an early and pharmacologically actionable phase of paraganglioma organization.

AB - Tumours can be viewed as aberrant tissues or organs sustained by tumorigenic stem-like cells that engage into dysregulated histo/organogenetic processes. Paragangliomas, prototypical organoid tumours constituted by dysmorphic variants of the vascular and neural tissues found in normal paraganglia, provide a model to test this hypothesis. To understand the origin of paragangliomas, we built a biobank comprising 77 cases, 18 primary cultures, 4 derived cell lines, 80 patient-derived xenografts and 11 cell-derived xenografts. We comparatively investigated these unique complementary materials using morphofunctional, ultrastructural and flow cytometric assays accompanied by microRNA studies. We found that paragangliomas contain stem-like cells with hybrid mesenchymal/vasculoneural phenotype, stabilized and expanded in the derived cultures. The viability and growth of such cultures depended on the downregulation of the miR-200 and miR-34 families, which allowed high PDGFRA and ZEB1 protein expression levels. Both tumour tissue- and cell culture-derived xenografts recapitulated the vasculoneural paraganglioma structure and arose from mesenchymal-like cells through a fixed developmental sequence. First, vasculoangiogenesis organized the microenvironment, building a perivascular niche which in turn supported neurogenesis. Neuroepithelial differentiation was associated with severe mitochondrial dysfunction, not present in cultured paraganglioma cells, but acquired in vivo during xenograft formation. Vasculogenesis was the Achilles' heel of xenograft development. In fact, imatinib, that targets endothelial-mural signalling, blocked paraganglioma xenograft formation (11 xenografts from 12 cell transplants in the control group versus 2 out of 10 in the treated group, P = 0.0015). Overall our key results were unaffected by the SDHx gene carrier status of the patient, characterized for 70 out of 77 cases. In conclusion, we explain the biphasic vasculoneural structure of paragangliomas and identify an early and pharmacologically actionable phase of paraganglioma organization.

U2 - 10.1007/s00401-017-1799-2

DO - 10.1007/s00401-017-1799-2

M3 - Article

C2 - 29305721

VL - 135

SP - 779

EP - 798

JO - Acta Neuropathologica

JF - Acta Neuropathologica

SN - 0001-6322

IS - 5

ER -